EP3765488A1 - Procédé de fabrication d'analogue de pthrp - Google Patents

Procédé de fabrication d'analogue de pthrp

Info

Publication number
EP3765488A1
EP3765488A1 EP19709065.7A EP19709065A EP3765488A1 EP 3765488 A1 EP3765488 A1 EP 3765488A1 EP 19709065 A EP19709065 A EP 19709065A EP 3765488 A1 EP3765488 A1 EP 3765488A1
Authority
EP
European Patent Office
Prior art keywords
leu
lys
arg
fragment
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19709065.7A
Other languages
German (de)
English (en)
Inventor
Walter Cabri
Ivan DE PAOLA
Antonio Ricci
Andrea ORLANDIN
Ivan GURYANOV
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fresenius Kabi Ipsum SRL
Original Assignee
Fresenius Kabi Ipsum SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fresenius Kabi Ipsum SRL filed Critical Fresenius Kabi Ipsum SRL
Publication of EP3765488A1 publication Critical patent/EP3765488A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis

Definitions

  • the present invention relates to a manufacturing process for an analogue of parathyroid hormone related peptide (PTHrP), abaloparatide and its related intermediates.
  • PTHrP parathyroid hormone related peptide
  • Abaloparatide is an analog of human parathyroid hormone related peptide, PTHrP (1-34), represented by Formula (I):
  • the medicinal product containing abaloparatide (marketed under the trade name TYMLOSTM), was approved by the U.S. Food and Drug Administration (FDA) in April 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
  • FDA U.S. Food and Drug Administration
  • WO97/02834 describes the synthesis of human PTH (1-34) and PTHrP analogues using Solid Phase Peptide Synthesis (SPPS), which involves step-by-step addition of amino acids which are Boc-protected at the amino terminus.
  • SPPS Solid Phase Peptide Synthesis
  • This method of peptide synthesis requires repeated deprotection cycles with strong acids such as trifluoroacetic acid (TFA), for the removal of the Boc-protecting group at each addition step.
  • TFA trifluoroacetic acid
  • the process requires the use of Hydrogen Fluoride (HF) for final cleavage of the peptide from the resin.
  • Hydrogen fluoride is a highly toxic and corrosive compound and its use is not recommended in large scale production of pharmaceutical compounds. As an overall consequence, these drawbacks result in an extremely difficult and environment unfriendly process.
  • CN 106146648 discloses the synthesis of a truncated abaloparatide analogue (aa 1-33) by using a fragment-based approach consisting of the synthesis of three fragments (aa 1-15, aa 16-23 and aa 24-33) on different resins such as a chloro trltyl resin or a Rink amide resin, and condensation of these fragments using different coupling reagents.
  • One of the possible reasons for the low yield as well as the low purity of this approach is the risk of racemization of amino acid residues during the condensation of fragments in solution phase.
  • the product obtained that way needs to be purified further due to the presence of various impurities resulting in further yield loss.
  • the C-terminal carboxylic group of the fragment has to be activated prior to coupling.
  • the activation of C-terminal carboxylic groups of the fragments may however lead to both activated ester and oxazolone formation, which can be easily racemized in the basic conditions (N. L. Benoiton. Chemistry of Peptide Synthesis. Tailor and Francis Group. 2006). Therefore, the crude peptides obtained this way contain impurities corresponding to the isomerized product. Since the isomeric impurities have very similar retention times as the required target peptide, it is very difficult to separate these impurities from the desired target peptide. In summary, the activation step required for sufficient coupling of fragments often results in racemisation and hence the formation of impurities, which are extremely difficult to remove.
  • the present invention provides an improved process for the preparation of the peptide abaloparatide which is an analogue of parathyroid hormone related peptide.
  • the process of the present invention results in a product with high yield and high purity.
  • the invention relates to the preparation of abaloparatide of formula I through a fragment-based convergent synthesis.
  • the process for the preparation of abaloparatide comprises the steps of:
  • fragment A is a fragment having an achiral amino acid at the C-terminal reactive site
  • fragment B is a fragment, optionally bound to a resin at its C-terminal amino acid
  • the fragments A and B are protected fragments.
  • the invention relates to novel intermediates for the synthesis of abaloparatide wherein the intermediate may be fragment A or fragment B.
  • Fragment A is selected from
  • fragment B is selected from
  • P is a side chain protecting group or hydrogen, independently for each amino acid
  • PG is an alpha-amino protecting group or hydrogen
  • R’ is a resin or a carboxy protecting group
  • R is a resin or NH 2 .
  • peptide fragment or“fragment” describe a peptide with a partial abaloparatide amino acid sequence, that can be optionally attached to a resin at its C-terminal amino acid, and that can be protected or unprotected.
  • protected fragment or“protected peptide fragment” describe a fragment which bears either a terminal protecting group or side-chain protecting groups, or both of them.
  • terminal protecting group refers to a protecting group for the alpha- amino group of an amino acid or of a peptide, or a peptide fragment.
  • the type of the terminal protecting group used is depending on the type of resin used and on the protective groups required for side chain protection.
  • the terminal protecting group preferably is tert-butyloxycarbonyl (Boc); and wherein fragment B is used, which preferably is linked to a Rink amide resin, the terminal protecting group preferably is 9-fluorenylmethyloxycarbonyl (Fmoc).
  • side-chain protecting group is a protecting group for an amino acid side-chain functional group which is not removed when the terminal protecting group for an amino acid is removed.
  • side-chain protecting groups are included to protect side chains of amino acids which are particularly reactive or labile, to avoid side reactions and/or branching of the growing molecule.
  • acid-labile protecting groups such as tert- butyloxycarbonyl (Boc), tert-butyl (tBu), trityl (Trt), 2,2,4,6,7-pentamethyldihydrobenzofuran-5- sulfonyl (Pbf) etc.
  • the criterion for selecting side-chain protecting groups is that the protecting group should generally be stable to the reagent under the reaction conditions selected for removing the terminal protecting group at each step of the synthesis and should be removable upon completion of the synthesis of the desired amino acid sequence under reaction conditions that will not alter the peptide chain.
  • Resin is used to describe a solid support suitable to perform peptide synthesis.
  • Resin in the present context may be selected from the group comprising Rink amide resin (RAM resin), Rink acid resin, Rink amide MB HA resin, trityl based resin, Sieber resin and Wang resin.
  • Preferred resins are the 2-chloro trityl chloride resin (CTC resin), preferably for preparation of fragment A, and the Rink amide resin, preferably for preparation of fragment B and/or preparation of abaloparatide.
  • the carboxylic group of a C-terminal amino acid can be attached to a resin.
  • it can be in the form of a primary amide (when R is NH 2 ) or it can be protected with a carboxy protecting group such as an ester. In the latter cases, the coupling of these fragments is performed in Liquid Phase Peptide Synthesis.
  • the ester is preferably an ester that is stable in basic conditions, i.e. orthogonal to the terminal protecting groups.
  • the ester is tert-butyl ester, allyl ester or benzyl ester. More preferably, the ester is tert-butyl ester, which is removable in acidic conditions.
  • the present invention in one aspect, relates to the preparation of abaloparatide, represented by formula I:
  • Abaloparatide is prepared by fragment-based convergent synthesis, comprising coupling of peptide fragments.
  • the process for the preparation of abaloparatide comprises the steps of:
  • fragment A has an achiral amino acid at the C-terminal reactive site
  • fragment B is optionally bound to a
  • the peptide fragments in step a) are protected peptide fragments.
  • the peptide fragment A and peptide fragment B can both be prepared by a fragment-based convergent approach starting from shorter peptides, both in SPPS or LPPS.
  • peptide fragment A and peptide fragment B can also be prepared using step by step SPPS by coupling of amino acids according to the required sequence to the terminal amino acid residue attached to the resin using a coupling reagent and an activating agent.
  • the resin is activated by the removal of the protecting group.
  • the activated resin is coupled with the first amino acid wherein the amino acid is protected by a terminal protecting group and optionally a side-chain protecting group. Thereafter the following steps are repeated with different amino acids until the desired fragment, which is attached to the resin, is formed: i) removal of the terminal protecting group of amino acid
  • the terminal protecting group may be removed by treatment with a base.
  • the base may be an inorganic or organic base.
  • the base is an organic base selected from the group consisting of piperidine, piperazine, DBU and diethylamine, preferably piperidine. Even more preferably, the terminal protecting group is removed with 20% piperidine in DMF.
  • the coupling of amino acids takes place in the presence of a coupling reagent.
  • the coupling reagent may be selected from the group consisting of N,N'-diisopropylcarbodiimide (DIC), N,N’-dicyclohexylcarbodiimide (DCC), (Benzotriazol-l- yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP), 2-(7-Aza-lH-benzotriazole-l- yl)-l,l,3,3-tetramethyluronium hexafluorophosphate (HATU), 2-(lH-benzotriazole-l-yl)- l,l,3,3-tetramethyluronium hexafluorophosphate (HBTU) and N-(3-di mcthylam i nopropyl )-N'- ethylcarbodiimide (EDC
  • the coupling reaction is further facilitated by the addition of an additive.
  • the additive is selected from the group consisting of l-hydroxybenzotriazole (HOBt), 2-hydroxypyridine N-oxide, N- hydroxysuccinimide, l-hydroxy-7-azabenzotriazole, endo-N-hydroxy-5-norbornene-2,3- dicarboxamide and ethyl-2-cyano-2-hydroxyimino acetate (also known as OxymaPure).
  • the reaction is carried out in the presence of ethyl-2-cyano-2-hydroxyiminoacetate.
  • step iii) possible unreacted sites after resin loading and after each coupling are blocked (“capped”) to prevent any side reactions and the formation of truncated sequences.
  • Capping is achieved by a short treatment of the peptide resin with a large excess of a highly reactive unhindered reagent, which is chosen according to the reactive site to be capped.
  • a highly reactive unhindered reagent which is chosen according to the reactive site to be capped.
  • the reagent is an acid derivative, such as an anhydride or a carboxyl chloride, in a basic medium.
  • acetic anhydride, or benzoyl chloride, and a base, for instance diisopropylethylamine, are used.
  • the reagent is an alcohol in a basic medium, such as methanol with diisopropylethylamine.
  • a basic medium such as methanol with diisopropylethylamine.
  • peptide fragments prepared as described above are optionally cleaved from the resin prior to step a) for the preparation of abaloparatide.
  • step a) coupling of a protected peptide fragment A with a protected peptide fragment B takes place to obtain protected abaloparatide or a shorter protected fragment.
  • Fragment A is selected from
  • Fragment B is selected from
  • P are a side-chain protecting groups or hydrogen, independently for each amino acid
  • PG is an alpha-amino protecting group or hydrogen
  • R’ is a resin or a carboxy protecting group
  • R is a resin or NH 2 .
  • the coupling of peptide fragments for the synthesis of abaloparatide or a shorter fragment thereof takes place in the presence of a coupling reagent.
  • the coupling reagent is selected from the list of coupling reagents reported above for step ii). More preferably, the reaction is carried out in the presence of N,N'-diisopropylcarbodiimide (DIC) .
  • DIC N,N'-diisopropylcarbodiimide
  • the coupling reaction is further facilitated by the addition of an additive.
  • the additive is selected from the list of additives reported above for step ii).
  • the reaction is carried out in the presence of ethyl-2-cyano-2-hydroxyimino acetate.
  • the coupling reaction may be carried out in the presence of a base, for instance a tertiary amine.
  • a base for instance a tertiary amine.
  • the base is selected from the group consisting of diisopropylethylamine, triethylamine, N-methylmorpholine and N-methylpiperidine; more preferably, the reaction is carried out in the presence of diisopropylethylamine.
  • the coupling of fragments takes place in the presence of a solvent selected from the group consisting of dimethylformamide, dimethylacetamide, dimethylsulfoxide, dichloromethane, chloroform, tetrahydrofuran, 2-methyl tetrahydrofuran, N-methylpyrrolidone and N- methylpyrrolidine.
  • a solvent selected from the group consisting of dimethylformamide, dimethylacetamide, dimethylsulfoxide, dichloromethane, chloroform, tetrahydrofuran, 2-methyl tetrahydrofuran, N-methylpyrrolidone and N- methylpyrrolidine.
  • the coupling is carried out in DMF.
  • the achiral amino acid at the C-terminal reactive site of fragment A may be a natural or an un natural amino acid.
  • the achiral amino acid may be selected from glycine (Gly) and 2- aminoisobutyric acid (Aib).
  • step b) abaloparatide or the shorter fragment thereof is deprotected and optionally cleaved from the resin by treatment with an acid; preferably with trifluoroacetic acid.
  • an acid preferably with trifluoroacetic acid.
  • the cleavage may be performed with a mixture TFA/water/TIPS/dodecanethiol (v/v 94/2.5/1/2.5).
  • step c) abaloparatide or the shorter fragment thereof obtained from step b) may be optionally purified by crystallization or chromatographic techniques well known in the art.
  • the coupling of peptide fragment A with fragment B, optionally bound to a resin is a promising alternative to step-by-step SPPS to produce the target peptides (i.e. abaloparatide or a shorter fragment thereof) because it reduces the formation rate of truncated sequences and unwanted isomeric forms, which are difficult to separate from the target peptide.
  • peptide fragment A is PG-Ala-Val-Ser(P)-Glu(P)-His(P)-Gln(P)-Leu-Leu-His(P)-Asp(P)-Lys(P)-Gly-OH (Fragment 1, (1-12)); and
  • R is a resin and P and PG are as defined above.
  • the coupling of Fragment 1 with Fragment 2 for the synthesis of abaloparatide takes place in the presence of a coupling reagent and an additive as described above. More preferably the coupling takes place in the presence of DIC and ethyl-2-cyano-2-hydroxy-imino-acetate.
  • Fragment 1 and Fragment 2 can be prepared by stepwise SPPS as explained above.
  • the fragments can be prepared by a fragment-based convergent approach starting from shorter peptides, both in SPPS or LPPS.
  • peptide Fragment 2 (13-34) is obtained by coupling of peptide Fragment 3
  • R is a resin and P and PG are as defined above.
  • the coupling of Fragment 3 with Fragment 5 for the synthesis of Fragment 2 takes place in the presence of a coupling reagent and an additive, as described above for step a). More preferably, the coupling takes place in the presence of DIC and ethyl-2-cyano-2-hydroxy-imino- acetate.
  • the coupling being carried out in the presence of DIC and ethyl-2-cyano-2-hydroxy-imino-acetate; and subsequent Fmoc deblocking.
  • R is a resin and P and PG are as defined above.
  • the coupling of Fragment 4 with Fragment 5 for the synthesis of abaloparatide takes place in the presence of a coupling reagent and an additive as described above. More preferably the coupling takes place in the presence of DIC and ethyl-2-cyano-2-hydroxy-imino-acetate.
  • Fragment 4 and Fragment 5 can be prepared by stepwise SPPS as explained above.
  • the fragments can be prepared by a convergent approach starting from shorter peptides, both in SPPS or LPPS.
  • Fragment 4 (1-29) can be obtained by coupling of peptide Fragment 1
  • R’, P and PG are as defined above.
  • the coupling of Fragment 1 with Fragment 3’ for the synthesis of Fragment 4 takes place in the presence of a coupling reagent and an additive, as described above for step a). More preferably the coupling takes place in the presence of DIC and ethyl-2-cyano-2-hydroxy-imino- acetate.
  • the obtained compound is optionally deprotected and/or cleaved from the resin by treatment with an acid; preferably with trifluoroacetic acid. Subsequently, it is further reacted in a coupling reaction with another fragment or it is purified.
  • crude abaloparatide obtained by deprotection and cleavage from the resin is purified by using various methods known in the art.
  • the purification is performed by preparative HPLC.
  • a solution of the peptide is loaded into an HPLC column with a suitable solid phase, preferably Cl 8 or C8 modified silica, and a suitable aqueous mobile phase containing one or several organic solvents, preferably acetonitrile or methanol or mixtures thereof, is passed through the column. A gradient of the organic solvent is applied, if necessary.
  • the peptide with desired purity is collected and optionally lyophilized.
  • the peptide sequences of fragments A and B are partial sequences of abaloparatide, which are suitable for the coupling strategy that involves coupling via a site with an achiral amino acid at the C terminus of fragment A.
  • Step 1 Preparation of Boc-Ala-Val-Ser(tBu)-Glu(tBu)-His(Trt)-Gln(Trt)-Leu-Leu-His(Trt) ⁇ Asp(tBu)-Lys(Boc)-Gly-OH
  • Synthesis of the peptide fragment 1 was carried out by step-by-step SPPS using 2-chloro trltyl chloride resin (1.6 mmol/g). After swelling of 1.0 g of the resin using 5 ml of DCM, Fmoc-Gly- OH and DIEA (three-fold and six-fold excess, respectively, respect to the loading of the resin) in DMF were added.
  • the reaction mixture was stirred for 1 hour, the unreacted sites of the resin were capped using a DCM/MeOH/DIPEA 17/2/1 solution (2x15 min) and the resin was washed with DMF (4x5 mL).
  • the loading of the resin was checked by UV adsorption measurement after Fmoc deprotection and was found to be 0.8 mmol/g.
  • the amino acids were pre-activated by DIC and OxymaPure (three-fold excess of the reagents respect to the loading of the resin) before each coupling cycle during 3 min and then coupled to 200 mg of the resin in 60 min.
  • Fmoc-Lys(Boc)- OH, Fmoc-Asp(7Bu)-OH, Fmoc-His(Trt)-OH, Fmoc-Leu-OH, Fmoc-Gln(Trt)-OH, Fmoc- Glu(/Bu)-OH, Fmoc-Ser(7Bu)-OH, Fmoc-Val-OH and Boc-Ala-OH derivatives were used. The unreacted amino groups were capped each cycle with the mixture AC 2 0/DIPEA/DMF (2x30 min).
  • the Fmoc deprotection cycles were carried out by 20% solution of piperidine in DMF (2x2 ml, 5 min and 15 min) with following washing of the resin with DMF (4x2 ml). After coupling with last Boc-protected amino acid, dry peptide resin was suspended in 4 ml of TFA/DCM 1:99 (v/v) solution and stirred for 15 min. Then the resin was filtered and the solution was neutralized by DIEA. The cleavage was repeated 3 times and the collected fractions were evaporated. The resulted oil was washed with water (3 x 1 ml) and dried in vacuo to obtain a powder that was used in the next step without further purification.
  • Synthesis of the peptide fragment 2 was carried out by SPPS using Fmoc-protected Rink amide resin (200 mg, loading 0.65 mmol/g). After swelling of the resin in 2 ml of DMF, Fmoc group was removed by 20% solution of piperidine in DMF (2x2 ml, 5 min and 15 min) and the resin was washed with DMF (4x2 ml).
  • Dry peptide resin from step 3 was suspended in 4 ml of TFA/water/TIPS/dodecanethiol (v/v 94/2.5/1/2.5) and stirred for 4 h. Then the resin was filtered and washed with 2 ml of TFA. The organic solutions were collected and 15 ml of methyl /e/7-butyl ether were added. The solid residue was filtered, washed with methyl /e/7-butyl ether and dried to get crude abaloparatide with an HPLC crude purity of 81%.
  • the crude abaloparatide as obtained in step 4 was dissolved in 1 ml of a mixture ACN/water (v/v 2/8) and purified by reversed phase preparative HPLC using C18 Jupiter (Phenomenex) column and water and acetonitrile containing 0.1% of TFA (Eluents A and B, respectively). The following gradient of acetonitrile was used: 10% of Eluent B in 15 min, then from 10% to 40% of Eluent B in 60 min. The fractions containing the product with more than 99% purity were collected and lyophilized to obtain 170 mg of abaloparatide (yield 65%).
  • Synthesis of the peptide fragment 5 was carried out by SPPS using Rink amide resin (200 mg, loading 0.65 mmol/g). After swelling of the resin in 2 ml of DMF, Fmoc protective group was removed by 20% solution of piperidine in DMF (2x2 ml, 5 min and 15 min) and the resin was washed with DMF (4x2 ml).
  • Fmoc-Ala-OH, Fmoc-Thr(tBu)-OH, Fmoc-His(Trt)-OH, Fmoc-Leu- OH, Fmoc-Lys(Boc)-OH were pre-activated by DIC and OxymaPure (three-fold excess of the reagents respect to the loading of the resin) for 3 min and coupled to the resin in 60 min.
  • the unreacted amino groups were capped each cycle with the mixture Ac 2 0/DIPEA/DCM (2x30 min).
  • the Fmoc deprotection cycles were carried out as described above in order to finally obtain the title peptide fragment (coupled to the resin).
  • Step 2 Preparation of Fmoc-Lys(Boc)-Ser(tBu)-Ile-Gln(Trt)-Asp(tBu)-Leu-Arg(Pbf)- Arg(Pbf)- Arg(Pbf)-Glu(tBu)-Leu-Leu-Glu(tBu)-Lys(Boc)-Leu-Leu-Aib-OH (3)
  • Synthesis of the peptide fragment 3 was carried out by step-by-step SPPS using 2-chloro trltyl chloride resin (1.6 mmol/g). After swelling of 1.0 g of the resin using 5 ml of DCM, Fmoc-Aib- OH and DIEA (three-fold and six-fold excess, respectively, respect to the loading of the resin) in DMF were added. The reaction mixture was stirred for 1 hour, the unreacted sites of the resin were capped using a DCM/MeOH/DIPEA 17/2/1 solution (2x15 min) and the resin was washed with DMF (4x5 mF).
  • the loading of the resin was checked by UV adsorption measurement after Fmoc deprotection and was found to be 0.4 mmol/g.
  • the amino acids were pre-activated by DIC and OxymaPure (three-fold excess of the reagents respect to the loading of the resin) before each coupling cycle during 3 min and then coupled to 200 mg of the resin in 60 min.
  • Fmoc-Feu-OH, Fmoc-Fys(Boc)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Asp(OtBu)-OH, Fmoc- Gln(Trt)-OH, Fmoc-Ile-OH, Fmoc-Ser(tBu)-OH protected amino acids were used. The unreacted amino groups were capped each cycle with the mixture AC 2 0/DIPEA/DCM (2x30 min).
  • the Fmoc deprotection cycles were carried out by 20% solution of piperidine in DMF (2x2 ml, 5 min and 15 min) with following washing of the resin with DMF (4x2 ml). After coupling with last Fmoc- protected amino acid, dry peptide resin was suspended in 4 ml of TFA/DCM 1:99 (v/v) solution and stirred for 15 min. Then the resin was filtered and the solution was neutralized by DIPEA. The cleavage was repeated 3 times and the collected fractions were evaporated. The resulted oil was washed with water (3 x lml) and dried in vacuo (yield 82%).
  • Step 4 Purification of Abaloparatide.
  • the crude peptide was purified as described in Example 1 to obtain 175 mg of Abaloparatide (Yield 72%).
  • Synthesis of the peptide fragment 24-34 was carried out by SPPS using Rink amide resin (200 mg, loading 0.65 mmol/g). After swelling of the resin in 2 ml of DMF, Fmoc protective group was removed by 20% piperidine in DMF (2x2 ml, 5 min and 15 min) and the resin was washed with DMF (4x2 ml).
  • the unreacted amino groups were capped using Ac 2 0/DIPEA/DMF mixture (2x30 min).
  • the intermediate Fmoc deprotection cycles were carried out as described above in order to obtain side-chain protected FEKFFAibKFHTA-Rink resin.
  • Synthesis of the peptide fragment 16-23 was carried out by SPPS using CTC resin (1.6 mmol/g). After swelling of 1.0 g of the resin using 5 ml of DCM, Fmoc-Feu-OH and DIPEA (three-fold and six-fold excess, respectively, respect to the loading of the resin) in DCM were added. The reaction mixture was stirred for 2 hours, the unreacted sites of the resin were capped using a DCM/MeOH/DIPEA 17/2/1 solution (2x15 min) and the resin was washed with DMF (4x5 mF). The loading of the resin was checked by UV adsorption measurement after Fmoc deprotection and was found to be 0.6 mmol/g.
  • the amino acids were pre-activated by DIC and OxymaPure (three fold excess of the reagents respect to the loading of the resin) before each coupling cycle during 3 min and then coupled to 200 mg of the resin in 60 min.
  • Fmoc-Glu(7Bu)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Feu-OH, Fmoc-Asp(7Bu)-OH, Fmoc-Gln(Trt)- OH derivatives were used. In case of Arg the couplings were repeated twice.
  • Synthesis of the peptide fragment 1-15 was carried out by SPPS using CTC resin (1.6 mmol/g). After swelling of 1.0 g of the resin using 5 ml of DCM, Fmoc-Ile-OH and DIEA (three-fold and six-fold excess, respectively, respect to the loading of the resin) in DCM were added. The reaction mixture was stirred for 2 hours, the unreacted sites of the resin were capped using a DCM/MeOH/DIPEA 17/2/1 solution (2x15 min) and the resin was washed with DMF (4x5 mL). The loading of the resin was checked by UV adsorption measurement after Fmoc deprotection and was found to be 0.5 mmol/g.
  • the amino acids were pre-activated by DIC and OxymaPure (three fold excess of the reagents respect to the loading of the resin) before each coupling cycle during 3 min and then coupled to 200 mg of the resin in 60 min.
  • Step 4a Condensation of fragments (16-23) + (24-34) with HBTU/HOBt/DIPEA
  • Fmoc deprotection was carried out by 20% piperidine in DMF (2x2 ml, 5 min and 15 min) with following washing of the resin with DMF (4x2 ml) to obtain side-chain protected QDLRRRELLEKLLAibKLHTA-Rink resin (fragment 16-34).
  • Step 4b Condensation of fragments (16-23) + (24-34) with DIC/Oxyma
  • Fmoc deprotection was carried out by 20% piperidine in DMF (2x2 ml, 5 min and 15 min) with following washing of the resin with DMF (4x2 ml) to obtain side- chain protected QDFRRREFFEKFFAibKFHTA-Rink resin (fragment 16-34).
  • Step 5a Condensation of fragments (1-15) + (16-34) with PyBOP/HOBt/DIPEA
  • the cleavage of the peptide was carried out with 2 ml of the mixture TFA / ethanedithiol / thiophenol / phenol / water (80:5:5:5:5 v/v/v/v/v) for 3 h.
  • the resin was filtered off, the product was precipitated in 5 ml of diethyl ether, washed twice with diethyl ether and dried to obtain crude abaloparatide with an HPFC purity of 1.58%.
  • Step 5b Condensation of fragments (1-15) + (16-34) with DIC/Oxyma.
  • the cleavage of the peptide was carried out with 2 ml of the mixture TFA / ethanedithiol / thiophenol / phenol / water (80:5:5:5:5 v/v/v/v/v) for 3 h.
  • the resin was filtered off, the product was precipitated in 5 ml of diethyl ether, washed twice with diethyl ether and dried obtain crude abaloparatide with an HPFC purity of 0.64%.

Abstract

La présente invention concerne un procédé de fabrication à base de fragments d'abaloparatide, qui est un analogue du peptide associé à l'hormone parathyroïde (PTHrP), et ses intermédiaires associé donnant un produit avec un rendement élevé et une pureté élevée.
EP19709065.7A 2018-03-12 2019-03-12 Procédé de fabrication d'analogue de pthrp Withdrawn EP3765488A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18161274 2018-03-12
PCT/EP2019/056162 WO2019175173A1 (fr) 2018-03-12 2019-03-12 Procédé de fabrication d'analogue de pthrp

Publications (1)

Publication Number Publication Date
EP3765488A1 true EP3765488A1 (fr) 2021-01-20

Family

ID=61691228

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19709065.7A Withdrawn EP3765488A1 (fr) 2018-03-12 2019-03-12 Procédé de fabrication d'analogue de pthrp

Country Status (2)

Country Link
EP (1) EP3765488A1 (fr)
WO (1) WO2019175173A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020202182A1 (fr) * 2019-03-29 2020-10-08 Mylan Laboratories Limited Procédé de préparation d'abaloparatide
WO2021144388A1 (fr) * 2020-01-15 2021-07-22 Fresenius Kabi Ipsum S.R.L. Procédé de synthèse du nangibotide
JP2023547889A (ja) * 2020-10-26 2023-11-14 パーデュー・リサーチ・ファウンデーション 脊椎融合を治療するための化合物、組成物、および使用の方法
WO2023223296A1 (fr) * 2022-05-20 2023-11-23 Radius Health, Inc. Procédé de fabrication d'abaloparatide
CN116023467A (zh) * 2022-12-28 2023-04-28 江苏诺泰澳赛诺生物制药股份有限公司 一种阿巴帕肽的固相合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723577A (en) 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
TW505654B (en) * 1996-07-30 2002-10-11 Hoffmann La Roche Synthesis of analogs of PTH and PTHrP
ES2637283T3 (es) * 2006-10-03 2017-10-11 Radius Health, Inc. Una composición estable que comprende PTHrP y usos de la misma
CN106146648B (zh) 2015-03-26 2020-06-12 深圳翰宇药业股份有限公司 一种甲状旁腺激素类似物的合成方法

Also Published As

Publication number Publication date
WO2019175173A1 (fr) 2019-09-19

Similar Documents

Publication Publication Date Title
EP3765488A1 (fr) Procédé de fabrication d'analogue de pthrp
JP5996618B2 (ja) ビバリルジンの製造方法
AU2007214088B2 (en) Synthesis of glucagon-like peptide
KR101238133B1 (ko) 엡티피바타이드 및 관련 중간체 화합물의 제조 방법
WO2008109079A2 (fr) Peptides à pureté élevée
EP3864032B1 (fr) Procédé pour la fabrication d'analogues de glp-1
US20200317721A1 (en) A process for preparing a glucagon-like peptide
KR20100036326A (ko) 프람린타이드의 생산 방법
US11566058B2 (en) Process for the preparation of high purity glucagon
WO2020254479A1 (fr) Procédé de fabrication de glucagon
JP2022527041A (ja) プレカナチドを製造する改善された方法
AU2014282839A1 (en) Peptide-resin conjugate and use thereof
WO2017127007A1 (fr) Procédé de préparation de peptides avec un lieur pswang
US7645858B2 (en) Method of peptide synthesis of peptides containing a proline residue or hydroxyproline residue at or adjacent to the C-terminal end of the peptide
CN114945580B (zh) 用于合成南吉博肽的方法
KR20160147235A (ko) 선별적 용해도를 갖는 트리페닐메탄 유도체 및 그의 용도
WO2023105497A1 (fr) Synthèse d'analogues de glp-1
US20230242581A1 (en) Synthesis of a guanylate cyclase agonist by fragments based approach

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201005

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GURYANOV, IVAN

Inventor name: CABRI, WALTER

Inventor name: DE PAOLA, IVAN

Inventor name: ORLANDIN, ANDREA

Inventor name: RICCI, ANTONIO

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20210908

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20220119